Browse by category

Preoperative Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) neither augment nor detract from metabolic and bariatric surgery (MBS), at least for the first 12 months postoperatively, according to the study by researchers from the School of Medicine, University of California, San Francisco. GLP-1 RAs use has risen dramatically with some patients treated with GLP-1 RAs1 later pursue MBS. However, the researchers noted that preoperative GLP-1 RA exposure influences post-op

Minister of Health (MoH) of Kuwait has issued new standards for regulating metabolic bariatric surgeries (MBS) and non-surgical interventional procedures in public and private healthcare facilities. The Ministry has established a comprehensive regulatory framework based on clear standards covering healthcare facilities, medical practitioners, patient selection and assessment, follow-up procedures, and monitoring of outcomes and complications. The standards take effect immedia

Researchers from the Netherlands and Yale School of Medicine - who evaluated sex differences in health status before and outcomes after metabolic and bariatric surgery (MBS) among men, premenopausal women, and postmenopausal women - have reported that men had more health conditions before MBS and lost less weight after surgery. Postmenopausal women showed a similar pattern but to a lesser extent. For the study, the researchers analysed data from the National Bariatric Surgery

In a new position paper, the American College of Physicians (ACP) has issued several recommendations on how policymakers can increase accessibility of obesity treatment for adults and address modifiable factors that contribute to obesity like diet and physical activity. The paper also includes further recommendations on reducing stigma associated with obesity, improving understanding of obesity among physicians and increasing access to healthy food. According to research from

A new approach to defining obesity could help physicians better determine which patients need more intensive treatment by focusing on the effects of excess adiposity on organs and tissues rather than relying primarily on whether a person meets a set of metabolic risk thresholds. Researchers from LSU's Pennington Biomedical Research Center examine the concept of "metabolically healthy obesity" and argue that a newer framework distinguishing preclinical obesity from clinical ob

Aqua Medical has announced the successful treatment of the first US patient in its FDA authorised Investigational Device Exemption (IDE) clinical trial evaluating the company's proprietary Proximal Intestinal Mucosal Ablation (PIMA) procedure for the treatment of type 2 diabetes. Aqua Medical is investigating a new diabetes procedure called proximal intestinal mucosal ablation (Illustration courtesy of Aqua Medical) Aqua Medical's investigational PIMA procedure utilises the c